ORGOOrganogenesis Holdings, Inc. Class A

CMS policy changes drove 58% revenue decline, but sequential recovery signals stabilization.

The latest update on Organogenesis Holdings centers on a cut to the assessed fair value and price target from US$3.00 to US$2.00, which marks a reduction of around one third. Analysts framing this shift with Hold ratings describe a mix of potential opportunity and clear near term challenges. This reflects a more cautious but still balanced view of risk and reward. As you read on, you will see how this revised price target fits into the evolving narrative around guidance, reimbursement...

In August 2026, Organogenesis Holdings Inc. reported second-quarter revenue of US$43.76 million and a net loss of US$96.27 million, alongside sharply reduced full-year 2026 revenue guidance and a US$75.00 million at-the-market equity offering. These results highlighted a very large year-over-year revenue contraction and a significantly wider loss per share, even as new Affinity clinical data added support to the company’s chronic wound care portfolio. We’ll now examine how this steep revenue...

Moby summary of Organogenesis Holdings Inc.'s Q2 2026 earnings call

Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales a